Tandem Multi-modal Plate Readers for a High Throughput Screening platform

项目总结： 斯克里普斯研究分子筛查中心(SRMSC)正在申请资金购买 两个微板阅读器，以取代其目前的uHTS Perkin Elmer Viewlux，后者已达到 生命的终结。ViewLux一直是高速微版成像的黄金标准；非常适合 用于对速度、可靠性和高质量数据要求较高的同时进行板井成像分析。 我们HTS屏幕平台上的集成Viewlux阅读器非常好地满足了我们的需求 它的第一次分期付款在2005年。然而，在大约15年的服务之后，可靠性已经成为一个关键问题 Perkin Elmer的停产(2017)和服务支持加剧了 所有零部件的停产制造。到目前为止，上没有当前的阅读器 市场与Viewlux的速度相等，这在任何时候都是特别有问题的 越来越需要执行弱光发光和Bret读数。不足为奇的是，许多 综合性HTS筛查中心(医药和学术)现在必须依赖多个阅读器 以满足HTS自动化吞吐量需求，同时保持高质量和可靠的数据。高 通量筛选(HTS)已成为探针开发和药物开发中不可缺少的工具 发现和斯克里普斯研究分子筛选中心(SRMSC)一直走在前列 在斯克里普斯和其他学术机构为NIH调查人员服务。自在中国建立业务以来 2005年，我们筛选了300多个目标，为我们的 斯克里普斯和其他机构的合作者。超过122篇科学论文和无数 演示文稿展示了我们产生优秀研究驱动数据的能力。我们的筛查结果 已经开发了77个生物活性分子探针作为治疗的新药物靶点 生物医学研究已经成功地作为INDS进入临床试验测试阶段，并最终 NDA/FDA药物。串联式多模式车牌阅读器将取代陈旧的ViewLux；允许 SRMSC履行其目前的HTS筛查义务，并继续为NIH社区提供服务，网址为 拥有全面的HTS药物发现能力的大型公司。

PROJECT SUMMARY: The Scripps Research Molecular Screening Center (SRMSC) is requesting funds for the purchase of two microplate readers as a replacement for its current uHTS Perkin Elmer Viewlux which has reached end of life. The ViewLux has been the gold standard for high-speed microplate imaging; ideally suited for simultaneous plate-well imaging analysis where speed, reliability and high quality data is required. The integrated Viewlux reader on our HTS screening platform has served our needs admirably since its initial installment in 2005. However, after ~15-years of service, reliability has become a critical issue compounded by Perkin Elmer’s end of production (2017) and service support exacerbated by the discontinued manufacture of all parts/components. As of date, there is not a current reader on the market that equals the speed of the Viewlux, which is especially problematic with respect to ever increasing need to perform low light luminescence and BRET readouts. Not surprisingly, many comprehensive HTS screening centers (both Pharma & academic) must now rely on multiple readers to meet HTS automation throughput needs while maintaining high quality and reliable data. High Throughput Screening (HTS) has become an indispensable tool for probe development and drug discovery and the Scripps Research Molecular Screening Center (SRMSC) has been in the forefront in serving NIH investigators at Scripps and other academic institutes. Since establishing operations in 2005, we have screened over 300 targets to generate more than 100 million data points for our collaborators at Scripps and at other institutions. Over 122 scientific papers and numerous presentations demonstrate our ability to produce excellent research-driven data. Our screening results have led to the development of over 77 bioactive molecular probes as novel drug targets for biomedical studies that have successfully advanced as INDs for clinical trial testing and eventually NDA/FDA drugs. The tandem multi-modal plate readers will replace the aged ViewLux; allowing SRMSC to fulfill its current HTS screening obligations and continue to serve the NIH community at large with its comprehensive HTS drug discovery capabilities.